R6/2 transgenic mice with expanded CAG repeats (N 300) have a surprisingly prolonged disease progression and longer lifespan than prototypical parent R6/2 mice (carrying 150 CAGs); however, the mechanism of this phenotype amelioration is unknown. We compared gene expression profiles in the striatum of R6/2 transgenic mice carrying~300 CAG repeats (R6/2 Q300 transgenic mice) to those carrying~150 CAG repeats (R6/2 Q150 transgenic mice) and littermate wildtype controls in order to identify genes that may play determinant roles in the time course of phenotypic expression in these mice. Of the top genes showing concordant expression changes in the striatum of both R6/2 lines, 85% were decreased in expression, while discordant expression changes were observed mostly for genes upregulated in R6/2 Q300 transgenic mice.
R6/2 transgenic mice with expanded CAG repeats (N 300) have a surprisingly prolonged disease progression and longer lifespan than prototypical parent R6/2 mice (carrying 150 CAGs); however, the mechanism of this phenotype amelioration is unknown. We compared gene expression profiles in the striatum of R6/2 transgenic mice carrying~300 CAG repeats (R6/2 Q300 transgenic mice) to those carrying~150 CAG repeats (R6/2 Q150 transgenic mice) and littermate wildtype controls in order to identify genes that may play determinant roles in the time course of phenotypic expression in these mice. Of the top genes showing concordant expression changes in the striatum of both R6/2 lines, 85% were decreased in expression, while discordant expression changes were observed mostly for genes upregulated in R6/2 Q300 transgenic mice.
Upregulated genes in the R6/2 Q300 mice were associated with the ubiquitin ligase complex, cell adhesion, protein folding, and establishment of protein localization. We qPCR-validated increases in expression of genes related to the latter category, including Lrsam1, Erp29, Nasp, Tap1, Rab9b, and Pfdn5 in R6/2 Q300 mice, changes that were not observed in R6/2 mice with shorter CAG repeats, even in late stages (i.e., 12 weeks of age). We further tested Lrsam1 and Erp29, the two genes showing the greatest upregulation in R6/2 Q300 transgenic mice, for potential neuroprotective effects in primary striatal cultures overexpressing a mutated human huntingtin (htt) fragment. Overexpression of Lrsam1 prevented the loss of NeuN-positive cell bodies in htt171-82Q cultures, concomitant with a reduction of nuclear htt aggregates. Erp29 showed no significant effects in this model. This is consistent with the distinct pattern of htt inclusion localization observed in R6/ 2 Q300 transgenic mice, in which smaller cytoplasmic inclusions represent the major form of insoluble htt in the cell, as opposed to large nuclear inclusions observed in R6/2 Q150 transgenic mice. We suggest that the prolonged onset and disease course observed in R6/2 mice with greatly expanded CAG repeats might result from differential upregulation of genes related to protein localization and clearance. Such genes may represent novel therapeutic avenues to decrease htt aggregate toxicity and cell death in HD patients, with Lrsam1 being a promising, novel candidate disease modifier. © 2011 Elsevier Inc. All rights reserved.
Introduction
The presence of a single copy of an expanded CAG repeat region in the Huntington's disease (HD) gene is causative for developing this progressive, neurological disorder (Group, 1993) , with an inverse relationship existing between CAG length and age of disease onset (Orr and Zoghbi, 2007) . However, there is enormous variation in the age-at-onset, progression of disease symptoms, and post mortem pathology among patients (Rosenblatt et al., 2001; Wexler et al., 2004; Li et al., 2006) and recent studies have suggested that this variation is strongly heritable (Rosenblatt et al., 2001; Djousse et al., 2003; Wexler et al., 2004; Li et al., 2006) . Hence, there is widespread belief that other, currently unknown genes can modify HD pathogenesis.
Similar phenomena are observed in mouse models of HD, whereby different lengths of the CAG repeat affect the onset and progression of the disease phenotype. For example, this has been observed for the original R6/1 vs. R6/2 transgenic mice lines, carrying 115 and 150 CAG repeats, respectively (Mangiarini et al., 1996) , and YAC72 vs. YAC128 transgenic mice (Hodgson et al., 1999) . However, extended breeding of R6/2 transgenic mice lines exhibiting unstable CAG repeat
